Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1

Interventions

Carboplatin 41Paclitaxel 40pembrolizumab 38Cyclophosphamide 23Gemcitabine 22130-nm albumin-bound paclitaxel 21Doxorubicin 18Cisplatin 18Albumin-Bound Paclitaxel 18atezolizumab 16Taxes 15Capecitabine 13veliparib 10Nivolumab 9Docetaxel 9Bevacizumab 9olaparib 8liposomal doxorubicin 7Everolimus 7spartalizumab 6durvalumab 6Epirubicin 6trametinib 5pegfilgrastim 5eribulin 5Irinotecan 5Filgrastim 5iniparib 4binimetinib 4apatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Triple Negative Breast Neoplasms × gedatolisib × Clear all
NCT01920061 2022-09-13

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Pfizer

Phase 1 Completed
110 enrolled 80 charts
Breast

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT03243331 2021-01-07

An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer

Indiana University

Phase 1 Completed
18 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡